New Ways to Give Nivolumab: Does Dose Matter for Advanced Melanoma Patients?

Nivolumab, a drug used to treat advanced melanoma, was initially given based on a person's weight (3 mg/kg every two weeks). Then, in 2018, health providers started using a flat dose (240 mg every two weeks or 480 mg every four weeks) instead. This change was made without direct proof from clinical trials, simply based on some calculations. But what’s the real deal? Did patient outcomes change when the dosing method switched? A recent study compared how patients fared with these two different ways of getting their medication. The study found that there wasn’t a significant difference in how patients responded or how long they lived. This raises a question: if weight-adjusted dosing didn't show better results, could a one-size-fits-all approach save resources and still provide effective treatment? Or should health providers keep weighing the costs and benefits of each method?